Almirall's Klisyri represents a significant step forward in the treatment of AK due to its short treatment protocol of a once-daily application for 5 days.
ANI's new executive team includes Christopher Mutz as chief commercial officer and head of rare diseases, Ori Gutwerg as senior vice president of generics, and Davinder Singh as general manager of Canadian operations.
Based on estimates, generic competition in the United States for seven complex products in AAM's analysis would yield annual savings between $600 million and $1.7 billion, with a median savings estimate of $1.3 billion.